Hikal Limited (HIKAL)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 13 August 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹212.84 ↓ 16.75% (1Y)

🎯 Key Takeaways

Hikal Limited is in a strategic transition phase, shifting focus from its legacy crop protection business toward high-margin pharmaceuticals and Animal Health segments, while actively managing legacy liabilities and remediation costs. Management is targeting 15-16% revenue growth in FY27 and Rs.
Revenue declined 1.1% QoQ to ₹448 in Q3FY25.
⚠️ Execution risk in USFDA remediation: Ongoing regulatory challenges could delay product launches or expansions in key markets, directly impacting reven

Market Cap

₹2,484

P/E Ratio

33.4

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About HIKAL 📊 Interactive Charts

📖 The Story

Hikal Limited is in a strategic transition phase, shifting focus from its legacy crop protection business toward high-margin pharmaceuticals and Animal Health segments, while actively managing legacy liabilities and remediation costs. Management is targeting 15-16% revenue growth in FY27 and Rs. 400 crores revenue by FY30, underpinned by capacity expansion, regulatory progress, and sustainability initiatives. The company is rebuilding profitability after a period of margin pressure and exceptional charges, with a clear emphasis on operational recovery and de-risking through debt reduction.

📰 What's Happening

In Q1 FY27, Hikal reported consolidated revenue of ₹403 crores, up 6.2% YoY, driven by 15.2% growth in pharmaceutical revenue to ₹233 crores, supported by strong demand in oncology and CNS APIs. EBITDA margin expanded by 260 bps to 9.2%, aided by ₹9 crores of exceptional income that reversed prior provisions. The company commissioned a cGMP pilot plant in Pune and achieved EcoVadis Gold rating, reinforcing its sustainability credentials. Management highlighted progress on USFDA remediation and expansion of CDMO capabilities as key growth enablers. Capital expenditure of ₹45 crores was directed toward capacity enhancement, while net debt declined to ₹685 crores from ₹815 crores, reflecting disciplined deleveraging amid remediation costs.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	545	388	435	448	514	407	453	448
Operating Profit	88	51	59	65	95	59	75	76
OPM %	16.1%	13.0%	13.2%	14.5%	18.4%	14.3%	16.5%	16.1%
Net Profit	36	7	13	16	34	5	18	17
EPS	₹2.92	₹0.56	₹1.02	₹1.31	₹2.76	₹0.41	₹1.48	₹1.39

The company's financial trajectory shows a clear inflection point: after peaking at ₹545 crores revenue and ₹36 crores net profit in Q4FY23, Hikal experienced a sharp decline in profitability, with standalone profit before tax turning negative to ₹(75) crores in Q1 FY27. However, recent quarters exhibit stabilization — revenue has held steady at ₹403 crores for two consecutive quarters, while EBITDA margin improved from 13% in FY24 to 9.2% in FY27, and EBITDA rose 47.4% YoY to ₹37 crores. This recovery is being driven by pharma growth and cost optimization, despite ongoing margin pressure in crop protection and one-time remediation expenses. The sequential improvement in profitability from ₹5 crores NP in Q1 FY25 to ₹7 crores in the latest quarter signals early traction in the turnaround.

🔮 Management Outlook & What's Next

Management expressed confidence in a stepwise recovery of revenues and profitability through FY27, citing improved demand visibility, expanding CDMO opportunities, and continued operational excellence. Key targets include 15-16% revenue growth in FY27, 20%+ EBITDA margins in Animal Health, and Rs. 400 crores revenue by FY30, supported by capacity expansion and regulatory progress. Management also emphasized ongoing remediation efforts with the USFDA and strategic investments in pharma and sustainability as pillars of future growth. No specific forward guidance beyond FY27 targets was provided, but the tone was cautiously optimistic, underpinned by tangible progress in core segments.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Execution risk in USFDA remediation: Ongoing regulatory challenges could delay product launches or expansions in key markets, directly impacting revenue growth and margins. 2. Margin sustainability in crop protection: Despite pharma growth, input cost inflation continues to pressure crop protection margins, limiting near-term profitability from a historically significant segment. 3. Capital intensity of transformation: High CapEx (₹45 crores in one quarter) and remediation costs may strain cash flow if pharma ramp-up or Animal Health targets are not met on schedule. 4. Market perception and sentiment: The company's recent shift away from legacy businesses has not yet translated into consistent profitability, making it vulnerable to short-term investor skepticism and sector-specific headwinds.

📋 Recent Filings

🧠 Analyst's Read

Hikal is undergoing a strategic pivot from a commodity-driven crop protection business to a more defensible, higher-margin pharmaceutical and Animal Health model, with early signs of operational stabilization. Investors should monitor execution of the USFDA remediation plan and the pace of CDMO revenue growth as key catalysts for margin recovery. While the financial turnaround is still in early stages, the combination of debt reduction, sustainability recognition, and targeted reinvestment suggests a deliberate, long-term transformation — making near-term profitability and regulatory progress the primary watchpoints.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on HIKAL

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-13.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when HIKAL files new disclosures

Track HIKAL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track HIKAL — Free

Free account · 2 AI queries/day